Manidipina Eg

Manidipine, the active ingredient in Manidipina Eg, is a calcium channel blocker of the dihydropyridine class presented as a tablet for oral use. It is indicated for the management of essential hypertension in adult patients, helping to lower elevated blood pressure by relaxing vascular smooth muscle.

GNH USA supplies Manidipina Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing products sourced from EU‑regulated manufacturers and ensuring quality and regulatory compliance through rigorous quality‑assurance processes.

Manidipine is a dihydropyridine calcium channel blocker used to treat disorders of elevated blood pressure. - Essential hypertension: reduces systolic and diastolic blood pressure in adult patients. - Isolated systolic hypertension: lowers high systolic pressure, improving cardiovascular risk profile. - Hypertension in elderly patients: provides effective blood pressure control with a favorable tolerability profile.

Manidipine may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often occurring after dose initiation. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: sensation of light‑headedness, especially when standing. - Nausea: mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Myocardial infarction: rare occurrence of heart attack. - Angioedema: swelling of face, lips, or throat requiring urgent care. - Hepatic dysfunction: abnormal liver enzymes or hepatitis. - Severe bradycardia: markedly slow heart rate. - Anaphylactic reaction: life‑threatening allergic response.

When prescribing or dispensing manidipine, several precautions should be observed to ensure safe use. - Monitor blood pressure: check regularly after initiation and dose adjustments. - Assess cardiovascular status: evaluate for existing heart disease before starting therapy. - Avoid abrupt discontinuation: taper the dose to prevent rebound hypertension. - Use caution in hepatic impairment: consider dose modification or close monitoring. - Pregnancy and lactation: discuss potential risks with a healthcare professional. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture.

Manidipine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase manidipine plasma concentrations. - Concomitant use with other antihypertensives (e.g., ACE inhibitors, ARBs): can cause excessive hypotension. - Grapefruit juice: can elevate drug levels leading to increased adverse effects.

Moderate Interactions (Monitor Closely): - Non‑dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem): additive cardiovascular effects. - Diuretics (e.g., thiazides, loop diuretics): may enhance blood pressure reduction. - Beta‑blockers (e.g., metoprolol, atenolol): monitor heart rate and blood pressure for additive effects.